CLINICAL_TRIALS trial_result · 2020-01-02

Clinical Trial Update: Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic [Phase 2]

Phase 2 trial evaluating a molecularly targeted therapy in BRAF wild-type metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Yale University | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-01-02